Overview

CTx-1301 Comparative Bioavailability Study

Status:
Completed

Trial end date:
2020-03-06

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301. In addition, this study seeks to characterize the pharmacokinetics of dexmethylphenidate and evaluate the safety and tolerability of CTx-1301.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cingulate Therapeutics

Treatments:

Dexmethylphenidate Hydrochloride